Last reviewed · How we verify
mesenchymal stem cell application
At a glance
| Generic name | mesenchymal stem cell application |
|---|---|
| Sponsor | King Edward Medical University |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phase 1 Study of VELGRAFT, a Living Cellular Construct, in the Management of Chronic Diabetic Foot Ulcers Which Have Attained Granulation Tissue (PHASE1)
- Safety Evaluation of MSC-based Therapy for Liver Cihcrosis Treatment (PHASE1)
- Objective Evaluation of Intradermal MSC-Derived Exosome Therapy on Facial Skin Quality (PHASE3)
- Study Comparing Two Methods for the Treatment of Large Chondral and Osteochondral Defects of the Knee (NA)
- Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes in the Treatment of Androgenic Alopecia (NA)
- Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes in the Treatment of Melasma (NA)
- Cellular Therapy for In Utero Repair of Myelomeningocele - The CuRe Trial (PHASE1, PHASE2)
- RenewDisc Trial: Endoscopic Discectomy and Autologous Stem Cell Therapy for Discogenic Low Back Pain
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- mesenchymal stem cell application CI brief — competitive landscape report
- mesenchymal stem cell application updates RSS · CI watch RSS
- King Edward Medical University portfolio CI